Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours
- 31 December 2007
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 43 (18), 2651-2657
- https://doi.org/10.1016/j.ejca.2007.07.025
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Clinical and In vitro Studies of Imatinib in Advanced Carcinoid TumorsClinical Cancer Research, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3Journal of Clinical Oncology, 2006
- Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumabJournal of Clinical Oncology, 2005
- Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsJournal of Clinical Oncology, 2005
- Carcinoid Heart DiseaseThe New England Journal of Medicine, 2003
- Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver MetastasesWorld Journal of Surgery, 2002
- Treatment of the Malignant Carcinoid SyndromeThe New England Journal of Medicine, 1986
- Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid SyndromeThe New England Journal of Medicine, 1983
- THE CLASSIFICATION OF CARCINOID TUMOURSThe Lancet, 1963